Metabolite Identification with Q-TOF MS

In preclinical drug development, metabolite identification (MetID) is a critical component of ADME (Absorption, Distribution, Metabolism, Excretion) characterization, which directly affects drug safety, efficacy, and regulatory compliance. Identifying in vivo and in vitro metabolites of lead compounds and preclinical candidates helps clarify metabolic pathways, evaluate metabolite toxicity, predict drug-drug interactions, and support IND (Investigational New Drug) submissions. Quadrupole Time-of-Flight Mass Spectrometry (Q-TOF MS) is the gold-standard technology for MetID, featuring high mass accuracy, high resolution, and rich fragmentation information, enabling rapid, accurate identification of known and unknown metabolites.

As a professional pharmaceutical CRO institution, PharmaAnalytica provides GLP-aligned Metabolite Identification Services using Q-TOF MS, tailored for small-molecule lead compounds and preclinical drug candidates. Our service covers in vitro (liver microsomes, hepatocytes) and in vivo (plasma, urine, feces, tissues) metabolite identification, leveraging advanced Q-TOF technology and professional data analysis capabilities to deliver comprehensive, reproducible, and regulatory-defensible MetID results, supporting lead optimization, safety assessment, and global regulatory submissions.

Core Service Content We Provide

1. Q-TOF MS Analytical Support
   • Customized Q-TOF MS method development, including chromatographic separation and mass spectrometry parameter optimization
   • High-resolution mass spectrometry detection to obtain accurate molecular weight and fragmentation information
   • Professional sample pretreatment: protein precipitation, solid-phase extraction (SPE), liquid-liquid extraction (LLE) to enrich metabolites
   • Data processing using advanced software for metabolite screening, identification, and confirmation
2. In Vitro Metabolite Identification
   • In vitro metabolic incubation using liver microsomes (human, rat, mouse, dog) and primary hepatocytes to simulate in vivo metabolic processes
   • Identification of phase I metabolites (oxidation, reduction, hydrolysis) and phase II metabolites (glucuronidation, sulfation, acetylation)
   • Metabolic stability evaluation and metabolite profiling under different incubation conditions (time, temperature, cofactors)
   • Screening of key metabolic enzymes involved in compound metabolism
3. In Vivo Metabolite Identification
   • Metabolite profiling in biological matrices (plasma, urine, feces, bile, and major tissues) from animal models (rodents, large animals)
   • Identification of major and minor metabolites, including conjugated and unusual metabolites
   • Quantification of relative abundance of key metabolites to clarify dominant metabolic pathways
   • Metabolite distribution analysis in target tissues to assess accumulation risks

PharmaAnalytica delivers comprehensive, regulatory-compliant Drug Distribution and Excretion Analysis reports, including: Detailed study protocols and SOPs (GLP-aligned).

• Basic Project Documents: Complete experimental protocol, incubation conditions (in vitro), animal grouping and administration scheme (in vivo), sample collection and storage records
• Q-TOF MS Method Report: Detailed chromatographic and mass spectrometry parameters, method optimization process, and quality control data
• Original Experimental Data: High-resolution mass spectra, fragmentation spectra, total ion chromatograms (TIC), extracted ion chromatograms (EIC), and peak integration data
• Metabolite Identification Results: List of identified metabolites (major and minor), molecular formulas, structural elucidation basis, relative abundance, and metabolic pathways
• In Vitro/In Vivo Metabolic Summary: Dominant metabolic pathways, key metabolites, and metabolic stability evaluation (if applicable)
• Comprehensive Analysis & Conclusion: Metabolic characteristics of the compound, metabolite safety risk assessment, and suggestions for lead optimization
• Regulatory Compliance Attachment: GLP-compliant traceable electronic data, metabolite database search records, and supporting materials for IND submissions

All data is fully compliant with ICH M4, ICH Q2(R1), FDA Guidance for Industry: Bioanalytical Method Validation, and EMA guidelines, making it suitable for preclinical IND enabling studies, clinical trial design, and non-clinical safety evaluation.

PharmaAnalytica's Technology Platform

PharmaAnalytica's Service Advantages

GLP-Compliant Validated Methods

Strict GLP standardized management, fully compliant with ICH M4, ICH Q2(R1), and FDA guidelines for MetID.

Expert Scientific Support

Professional technical team with rich experience in MetID, including mass spectrometry analysis and metabolic pathway interpretation.

Customer Sevice Design

Customized service scheme, supporting both in vitro and in vivo MetID, and high-efficiency project delivery.

Regulatory-Ready Deliverables

Complete regulatory-ready report, providing full-chain data support for drug R&D, safety assessment, and IND submissions.

Accurate and comprehensive metabolite identification is the key to reducing preclinical R&D risks and ensuring drug safety and efficacy. PharmaAnalytica's Metabolite Identification with Q-TOF service, supported by three high-performance Q-TOF MS platforms, integrates standardized GLP workflows, professional data interpretation, and regulatory compliance support. We are committed to providing reliable, efficient MetID solutions for global pharmaceutical clients, helping accelerate lead compound optimization, complete IND-enabling studies, and promote the safe and smooth progression of drug candidates from preclinical development to clinical trials.